Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Interferon alfa treatment of early primary myelofibrosis is associated with improved overall survival

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMlaak RobWeill Cornell Medical College in QatarMAMajed Al-NazerNationwide Children's HospitalJSJoseph M. ScanduraCornell University

Discussion

Loading...

Member takes

Implication

Cohort analysis shows interferon alfa enhances overall survival in early primary myelofibrosis, suggesting better treatment options.

Key Points

  • To determine the effects of interferon alfa on overall survival in early primary myelofibrosis.
  • Comparative cohort study with 92 patients diagnosed with primary myelofibrosis.
  • Data on demographics, clinical features, and treatment outcomes collected from medical records.
  • Utilized Kaplan-Meier methods and Cox proportional-hazards models for data analysis.
  • Median overall survival was longer in the interferon alfa group compared to control (18 years vs 14 years).
  • Overall response rate with interferon was 70%, with significant hematologic responses documented.
  • Independent analysis confirmed survival benefits associated with interferon treatment, irrespective of patient age.

Cite This Study

Rob et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d79chttps://doi.org/10.1182/blood-2025-2043
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis2025 · 1 citations
  2. 2Molecular response and outcomes in patients with myeloproliferative neoplasms treated with interferon in the real-world setting.2026 · 1 citations
  3. 3Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry2025
  4. 4A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis2024 · 16 citations
  5. 5Efficacy and safety of pegylated interferon alfa-2b in myeloproliferative neoplasms: A multicenter retrospective study of 210 patients2025